EMCURE

- Board of Directors approved the Scheme of Amalgamation on October 12, 2026. - Involves merging wholly owned subsidiaries Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited with the holding company Emcure Pharmaceuticals Limited. - Subject to obtaining necessary statutory and regulatory approvals.

- Emcure Pharmaceuticals received orders from the Income-tax Department imposing an aggregate penalty of Rs. 57,73,96,732 for Financial Years 2014-15 to 2020-21. - The company is evaluating legal remedies, including filing an appeal before the Appellate Authority.

- Emcure Pharmaceuticals Limited released its Investor Presentation for September 2026 detailing company overview, business segments, R&D capabilities, and strategic priorities. - Reported FY26 Operating Revenue of USD 1Bn+ (INR 92,035 Mn) with a YoY growth of +16.6%. - PAT for FY26 stood at INR 9,413 Mn representing a 33.1% growth YoY. - Outlined strategic pillars for FY26-FY30 focusing on deepening domestic franchise, scaling international portfolios, and commercializing differentiated R&D platforms.

- At its 45th AGM on September 21, 2026, Emcure Pharmaceuticals Limited approved changes to its Board composition. - Mr. Berjis Desai, Chairman and Non-Executive Non-Independent Director, retired upon the conclusion of the AGM. - Dr. Mukund Gurjar was re-appointed as a Whole-time Director for one year from August 28, 2026. - Mr. Satish Mehta was re-appointed as Managing Director & CEO for five years from April 01, 2027. - Mr. Raghu Kumar was appointed as an Independent Director for three years from August 06, 2026.